Nivolumab–relatlimab for adjuvant treatment of resected stage 3 or 4 melanoma in people 12 years and over [ID6475]

  • In development
  • GID-TA11586
  • Expected publication date: TBC

33790-Relatlimab-Nivolumab-for-Melanoma-V1.0-MAY2024-NON-CONF.pdf (nihr.ac.uk)